<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828710</url>
  </required_header>
  <id_info>
    <org_study_id>INO-2103-GC</org_study_id>
    <nct_id>NCT01828710</nct_id>
  </id_info>
  <brief_title>Myo-inositol on Human Semen Parameters</brief_title>
  <official_title>Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing IVF Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many clinical evidences suggest that Myo-inositol plays a crucial role in human reproduction.
      Also, it was shown that Myo-inositol concentration in the seminiferous tubules was higher
      than in serum, and interestingly it was increasing through the epididymis and the deferent
      duct mining that sperm cell before ejaculation are stored in a &quot;medium&quot; highly enriched in
      myo-inositol.

      Starting from this evidences, the investigators hypothesized that myo-inositol may be a
      possible factor able to improve the semen parameters of samples used in in vitro
      fertilization cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Samples of seminal fluid were obtained from two groups of patients undergoing to an IVF
      cycle: healthy normospermic subjects and subjects with oligoasthenoteratospermia (OAT, &lt; 15
      mil/ml).

      Semen volume, spermatozoa number and motility were evaluated during the initial semen
      analysis and after density gradient separation method. These parameters were evaluated before
      and after the administration of 4000mg/die of myo-inositol associated to 400 µg of folic acid
      (Inofolic lolipharma Rome) for three months.

      A third group of healthy normospermic subject were traded with 400 µg of folic acid for three
      months and was consider a control group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sperm concentration</measure>
    <time_frame>after 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Asthenozoospermia</condition>
  <condition>Oligospermia</condition>
  <arm_group>
    <arm_group_label>Myo-inositol normospermic</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myo-inositol OAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic acid normospermic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 normospermic patients treated with 400 µg of folic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol normospermic</intervention_name>
    <description>4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.</description>
    <arm_group_label>Myo-inositol normospermic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol OAT</intervention_name>
    <description>B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months</description>
    <arm_group_label>Myo-inositol OAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid normospermic</intervention_name>
    <description>Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.</description>
    <arm_group_label>Folic acid normospermic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Undergoing to IVF cycle OAT

        Exclusion Criteria:

        No undergoing to IVF cycle
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Palumbo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catania - Department of Surgery - Section of Obstetrics and Gynecology - Centre of Physiopathology of Reproduction</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianfranco Carlomagno, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>A.G.Un.Co. Obstetrics and gynaecology center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Physiopathology of Reproduction</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myo-inositol</keyword>
  <keyword>oligoasthenoteratospermia</keyword>
  <keyword>semen parameters</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligospermia</mesh_term>
    <mesh_term>Asthenozoospermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

